10-Q: Veru Inc. Reports Q2 2024 Results, Focuses on Enobosarm Development

Veru Inc. reported its financial results for the quarter ended March 31, 2024, highlighting a strategic shift towards enobosarm development and a decrease in overall net revenues.

Summary

• Veru Inc. reported a net loss of $10.0 million for the three months ended March 31, 2024, compared to a net loss of $33.8 million for the same period last year.
• Net revenues for the quarter were $4.1 million, a 37% decrease from $6.6 million in the prior year, primarily due to a shift in sales mix and the bankruptcy of a major telehealth customer.
• The company's gross profit decreased to $0.7 million, with a gross profit margin of 16%, compared to $4.1 million and 62% respectively in the prior year.
• Research and development expenses significantly decreased to $3.0 million from $17.9 million year-over-year, reflecting a strategic refocus on key drug candidates.
• Selling, general, and administrative expenses also decreased to $7.6 million from $12.8 million in the prior year.
• For the six months ended March 31, 2024, the net loss was $18.3 million on net revenues of $6.3 million, compared to a net loss of $72.5 million on net revenues of $9.1 million for the same period in 2023.
• The company's cash and cash equivalents increased to $34.7 million as of March 31, 2024, from $9.6 million at the end of September 2023, due to a public offering of common stock.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in reducing expenses and securing funding, the significant decrease in revenue and gross profit margin, along with the identified material weaknesses and legal proceedings, create a negative sentiment. The strategic shift towards enobosarm is a positive, but the uncertainty around sabizabulin and the company's ability to raise capital temper the overall outlook.

Positives

• The company's cash position significantly improved to $34.7 million due to a successful public offering.
• Research and development expenses were substantially reduced, reflecting a strategic focus on key programs.
• The company initiated a Phase 2b clinical trial for enobosarm in obesity, a key milestone for the program.
• The company resolved a commercial dispute, reducing potential liabilities.
• The company has secured a multi-year South African tender for female condoms.

Negatives

• Net revenues decreased by 37% year-over-year for the three months ended March 31, 2024.
• Gross profit margin decreased significantly to 16% for the quarter ended March 31, 2024.
• The company is not in compliance with a provision of the Jefferies Sales Agreement, which would prevent it from making additional sales under the agreement unless such non-compliance is waived.
• The company is ineligible to file new registration statements on Form S-3 until no earlier than March 1, 2025, which may impair its ability to raise capital.
• The company may not receive additional payments from Onconetix, Inc. related to the sale of ENTADFI assets.
• The company has paused further development of sabizabulin for viral-induced ARDS pending external funding.

Risks

• The company's ability to raise capital may be impaired due to its ineligibility to file new registration statements on Form S-3 until March 1, 2025.
• There is uncertainty regarding the receipt of future payments from Onconetix, Inc. for the sale of ENTADFI assets.
• The company's reliance on a single supplier for a key raw material for FC2 poses a supply chain risk.
• The company faces pricing pressure for FC2 in the global public health sector.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company is subject to ongoing shareholder litigation.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company plans to prioritize the development of enobosarm for obesity and seek external funding for sabizabulin. The company expects topline results from the Phase 2b clinical trial for enobosarm by the end of the fourth calendar quarter of 2024 and results from the Phase 2b extension clinical study in the second quarter of calendar year 2025.

Management Comments

• Management believes that enobosarm may address the unmet medical need for a drug that can prevent muscle loss while preferentially reducing fat in overweight or obese patients.
• Management intends to continue leveraging relationships with entities in the U.S. public health sector and expects revenue from the U.S. prescription channel to demonstrate growth.
• Management believes its current cash position and cash expected to be generated from sales of FC2 will be adequate to fund planned operations of the Company for the next 12 months.

Industry Context

The company's focus on enobosarm for obesity aligns with the growing market for weight loss drugs, particularly GLP-1 receptor agonists. The company's strategy to combine enobosarm with GLP-1 RAs addresses the issue of muscle loss associated with these drugs. The company's FC2 product continues to be relevant in the global public health sector for HIV/AIDS prevention and family planning.

Comparison to Industry Standards

• The company's decrease in revenue is concerning compared to industry trends, where many pharmaceutical companies are experiencing growth.
• The company's gross profit margin of 16% is significantly lower than the industry average for pharmaceutical companies, which is typically above 50%.
• The company's reduction in R&D spending is a strategic move, but it may impact its long-term growth prospects compared to peers who are investing heavily in research.
• The company's reliance on a single supplier for a key raw material is a risk that is not typical for larger pharmaceutical companies with more diversified supply chains.
• The company's ongoing shareholder litigation is a concern that is not common for well-established pharmaceutical companies.

Legal Proceedings

• The company is involved in several shareholder lawsuits alleging violations of securities laws and breach of fiduciary duty.
• The company is unable to estimate potential losses related to the shareholder litigation.

Stakeholder Impact

• Shareholders are impacted by the decrease in revenue and gross profit margin, as well as the ongoing shareholder litigation.
• Employees are impacted by the reduction in headcount and the strategic shift in the company's focus.
• Customers in the U.S. prescription channel are impacted by the consolidation in the telehealth industry.
• Customers in the global public health sector are impacted by pricing pressure for FC2.
• Creditors are impacted by the company's ongoing commercial dispute and its ability to raise capital.

Next Steps

• The company will continue to enroll patients in the Phase 2b clinical trial for enobosarm.
• The company will seek external funding for the development of sabizabulin.
• The company will continue to evaluate the collectability of the BWV Promissory Notes.
• The company will continue to implement its remediation plan for the material weaknesses in internal control over financial reporting.

Key Dates

Keywords

enobosarm, sabizabulin, FC2 Female Condom, obesity, metastatic breast cancer, ARDS, telehealth, clinical trial, pharmaceutical, biopharmaceutical